Harmony Biosciences (HRMY) Tops Q2 EPS by $1.05, provides guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $1.05. Revenue for the quarter came in at $172.8 million versus the consensus estimate of $173.24 million.

GUIDANCE:

Harmony Biosciences sees FY2024 revenue of $700-720 million, versus the consensus of $709.4 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Supermicro expands edge AI lineup with new Intel-powered systems